PHARMA MAR, S.A. «12345...» Page 3 out of 19 26/10/2023 17:38 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company files third quarter 2023 financial information and announces a conference call with analysts and investors. Register number: 25054 04/10/2023 18:37 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from September 1 to September 30, 2023. Register number: 24759 04/10/2023 17:39 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement during third quarter of the year 2023 Register number: 24757 06/09/2023 17:41 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from August 1 to August 31, 2023. Register number: 24365 27/07/2023 17:56 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company announces the commencement of the acquisition of treasury shares under the authorisation granted by the General Shareholders’ Meeting and the temporary suspension of the existing liquidity contract. Register number: 23910 27/07/2023 17:47 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company sends press release regarding first half 2023 results and announces a conference call with analysts and investors. Register number: 23908 27/07/2023 17:42 PHARMA MAR, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del primer semestre de 2023 Register number: 23906 19/07/2023 15:42 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner Immedica Pharma AB has received the full approval for commercialization for Zepzelca® (lurbinectedina) in Oman. Register number: 23673 11/07/2023 13:15 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner, Lotus Pharmaceutical CO., Ltd., has received accelerated marketing approval for Zepzelca® (lurbinectedina) in Taiwan. Register number: 23542 05/07/2023 17:42 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 01/04/2023 and 30/06/2023 Register number: 23453 Page 3 out of 19 «12345...»
